Could a vaccine slow Parkinson's? early trial tests UB-312

NCT ID NCT05634876

Completed Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a vaccine called UB-312 in 8 people with Parkinson's disease or multiple system atrophy. The vaccine is designed to train the immune system to attack abnormal clumps of a protein called alpha-synuclein, which are linked to these brain disorders. The main goals were to check safety and see if the vaccine triggers an immune response in the blood and spinal fluid.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UB-312 vaccine (synthetic peptide immunogen)
What this could lead to: If successful, this could lead to a vaccine-like treatment that helps the immune system target and clear harmful protein clumps in the brain, potentially slowing disease progression.
What could go wrong: This is a very early Phase 1 trial with only 8 participants, so safety and immune response are the main focus. It is too soon to know if it will work in people, and vaccines for brain diseases have historically been challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY PARKINSON DISEASE

Contacts and locations

Locations

NYU Langone Health

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.